Drug Profile
Letetresgene autoleucel - Adaptimmune
Alternative Names: GSK 794; GSK-3377794; NY-ESO SPEAR T-cell therapy - GlaxoSmithKline; NY-ESO TCR therapeutic; NY-ESO-1 T cell receptor; NY-ESO-1 TCR T; NY-ESO-1-specific T-cells - Adaptimmune; NY-ESO-1/LAGE-1-modified T-cells; NY-ESO-1c259T; NY-ESO-1c259-antigen-specific-T-cell-receptor-gene-therapy; NY-ESO-1c259-modified-T-cells; NY-ESO-1c259-TCR-transduced-lymphocytes; NY-ESO-1c259-TCR-transduced-T-cells; NY-ESO-c259TLatest Information Update: 21 Mar 2024
Price :
$50
*
At a glance
- Originator Adaptimmune
- Developer Adaptimmune; GlaxoSmithKline; Merck & Co
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Gastrointestinal cancer; Liposarcoma; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer; Synovial sarcoma
- No development reported Liver cancer; Prostate cancer
Most Recent Events
- 21 Mar 2024 Adaptimmune Therapeutics plans to launch letetresgene autoleucel for the treatment of synovial sarcoma and liposarcoma in the US in 2026 (IV)
- 01 Dec 2022 GlaxoSmithKline and Merck & Co terminates a phase I/II trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in Canada, Spain, Netherlands due to feasibility issues (IV) (NCT03709706) (EudraCT2018-003949-42)
- 01 Dec 2022 GlaxoSmithKline and Merck & Co terminates a phase I/II trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Canada, Spain, Netherlands due to feasibility issues (IV) (NCT03709706) (EudraCT2018-003949-42)